Viatris Inc. Form 8-K Summary
Business context and reporting period
Viatris filed this Current Report on Form 8-K on February 28, 2022, reporting that it entered into a Transaction Agreement with Biocon Biologics Limited on February 27, 2022. The transaction involves contributing Viatris’s biosimilars portfolio to Biocon Biologics through the acquisition of two Viatris subsidiaries.
Transaction economics and key financial terms
- Total consideration is up to $3.335 billion on a cash-free, debt-free basis.
- Consideration includes $2.0 billion in cash at closing, subject to specified adjustments.
- Viatris will receive a convertible preferred equity interest initially representing at least 12.9% of Biocon Biologics on a fully diluted basis. The interest may convert into a larger percentage under specified mandatory conversion events.
- Additional cash consideration includes $160 million payable on the second anniversary of closing and $175 million payable on April 8, 2024, subject to limited exceptions.
- If Biocon Biologics elects not to acquire assets and liabilities related to Viatris’s aflibercept product candidate, Viatris would not receive the $175 million payment.
- Viatris will provide transition services for an expected two-year period and receive cost reimbursement, subject to limitations, plus an annual markup of $44 million.
- The filing does not provide revenue, profit, cash flow, margin, debt, liquidity, or segment financial results for the reporting period.
Material changes versus the prior comparable period
The filing is transaction-focused and does not present comparative operating or financial results. Accordingly, it does not provide a clear basis for measuring changes in revenue, profitability, cash flow, margins, debt, or liquidity versus a prior period.
Conditions, outlook, commentary, and risks
- Closing is subject to customary conditions, including applicable antitrust waiting-period expiration, regulatory approvals including in India, and completion of approximately $500 million of committed equity financing from Biocon Limited and approximately $300 million from Serum Institute Life Sciences.
- The closing is not subject to a financing condition, although the transaction requires the specified committed financings and other financing arrangements.
- The transaction may be terminated if not completed by March 31, 2023, with a possible extension to June 30, 2023 for certain unresolved regulatory approvals.
- Viatris will be subject to specified pre-closing covenants and post-closing non-compete obligations relating to biosimilars. The parties will also enter into shareholder, employee matters, and transition services agreements.
- Biocon Biologics has agreed to use commercially reasonable efforts to target an initial public offering in India as early as late 2023; this is not a guaranteed timetable or outcome.
- Key risks include failure to obtain regulatory approvals, failure to complete the transaction, financing and timing issues, inability to achieve expected strategic benefits, tax and accounting uncertainty, integration and restructuring risks, litigation, regulatory changes, supply-chain and manufacturing issues, competition, product-development risks, cybersecurity, global economic conditions, and uncertainties related to demand, pricing, and reimbursement.
Important facts for investors to verify
- Whether all regulatory approvals and other closing conditions were satisfied and when the transaction actually closed.
- The final cash consideration after closing adjustments and whether the $160 million and $175 million deferred payments remain payable.
- Whether Biocon Biologics acquired the aflibercept-related assets and liabilities.
- The value, conversion terms, ownership percentage, and eventual liquidity of Viatris’s Biocon Biologics preferred equity interest.
- The financial statement treatment, including any gain, loss, impairment, tax effects, or discontinued-operations impact.
- The biosimilars portfolio revenue and profitability transferred, and the effect of the transaction on Viatris’s future results, debt, liquidity, and capital allocation.
- Whether the targeted Biocon Biologics IPO occurred and whether Viatris monetized or retained its equity interest.